A5086619939- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Historical Geopolitical and Social Dynamics
- Health Systems, Economic Evaluations, Quality of Life
- Lipid metabolism and disorders
- European Union Policy and Governance
- International Relations and Foreign Policy
- Cardiac Imaging and Diagnostics
- Diet and metabolism studies
- Post-Communist Economic and Political Transition
- Communism, Protests, Social Movements
- Systemic Lupus Erythematosus Research
- International Law and Aviation
- Global Peace and Security Dynamics
- Global Political and Social Dynamics
- Russia and Soviet political economy
- Historical and Contemporary Political Dynamics
- European Socioeconomic and Political Studies
- Pharmaceutical Economics and Policy
- Political and Social Issues
- Photochromic and Fluorescence Chemistry
- Antiplatelet Therapy and Cardiovascular Diseases
- Pharmacological Effects of Natural Compounds
- Systemic Sclerosis and Related Diseases
Harvard University
2000-2020
LabCorp (United States)
2015-2016
Wilmington University
2015
Wake Forest University
2006-2014
University of Alabama
2014
Emory University
2014
RELX Group (United States)
2014
Cardiovascular Institute of the South
2009
Novant Health Presbyterian Medical Center
2006
New York Law School
2005
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTCyclodextrin-adamantanecarboxylate inclusion complexes: studies of the variation in cavity sizeWilliam C. Cromwell, Katarina Bystrom, and Maurice R. EftinkCite this: J. Phys. Chem. 1985, 89, 2, 326–332Publication Date (Print):January 1, 1985Publication History Published online1 May 2002Published inissue 1 January 1985https://pubs.acs.org/doi/10.1021/j100248a029https://doi.org/10.1021/j100248a029research-articleACS PublicationsRequest reuse...
BackgroundCardiovascular outcomes for people with familial hypercholesterolaemia can be improved diagnosis and medical management. However, 90% of individuals remain undiagnosed in the USA. We aimed to accelerate early timely intervention more than 1·3 million at high risk heart attacks strokes by applying machine learning large health-care encounter datasets.MethodsWe trained FIND FH model using deidentified data, including procedure diagnostic codes, prescriptions, laboratory findings,...
Recent research has identified a unique population of ‘Lean Mass Hyper-Responders’ (LMHR) who exhibit increases in LDL cholesterol (LDL-C) response to carbohydrate-restricted diets levels ≥ 200 mg/dL, association with HDL 80 mg/dL and triglycerides ≤ 70 mg/dL. This triad markers occurs primarily lean metabolically healthy subjects, the magnitude increase LDL-C inversely associated body mass index. The lipid energy model been proposed as one explanation for LMHR phenotype posits that there is...
BackgroundBecause of variability in lipoprotein cholesterol content, low-density (LDL) frequently underrepresents or overrepresents the number LDL particles. Mipomersen is an antisense oligonucleotide that reduces hepatic production apolipoprotein B–100, sole LDL.ObjectiveTo characterize effects mipomersen on particle numbers as well subclass distribution using nuclear magnetic resonance (NMR) spectroscopy.MethodsWe compared tertiary results for direct measurement by NMR among 4...
A recent analysis of a commercially insured US population found fewer cardiovascular disease (CVD) events in high-risk patients attaining low levels low-density lipoprotein (LDL), as measured by LDL particle number (LDL-P) versus cholesterol (LDL-C). Here, we investigated the cost effectiveness LDL-lowering therapy guided LDL-P. Patients were selected from HealthCore Integrated Research Database and followed for 12 to 36 months. who achieved LDL-P <1,000 nmol/l placed into cohort, whereas...